BEARINGPOINT
14.1.2021 08:57:32 CET | Business Wire | Press release
Management and technology consultancy BearingPoint welcomes YouMeO, a strategy and innovation agency, and has created “YouMeO by BearingPoint” within the group. With the integration, BearingPoint strengthens its competencies in innovation strategy and design. YouMeO’s approach is based on design and collective intelligence, using methodologies from the social sciences and humanities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210113005729/en/
YouMeO, founded in 2014, is comprised of 15 innovation project managers and designers with skills in social sciences, ethnology, design, futurology, and gaming. Its integration is an opportunity for BearingPoint to expand its innovation portfolio by creating its own agency, “YouMeO by BearingPoint,” which will support strategic innovation projects at large companies and public organizations. YouMeO by BearingPoint will also stimulate an open ecosystem of skills in ethnography, semiology, behavioral psychology, and user research.
YouMeO by BearingPoint will be rolled out to all BearingPoint projects with a transformation dimension, change management, and innovation. Concretely, the team reinforces the existing support of the firm’s clients on three axes:
- Definition of a strategic and innovation vision
- Design for differentiation of experiences for customers and employees
- Reinvention of the company and its working methods.
Projects with clients will be collaborative and promote collective intelligence and empowerment.
The YouMeO by BearingPoint team will be strengthened through external recruitment and internally by BearingPoint consultants. This deployment will be done progressively within the firm in the coming months, with the objective to train around 100 consultants within 3 years.
Kiumars Hamidian, Managing Partner at BearingPoint: “The ability to innovate and create IP is one of the four core strengths highlighted in our Strategy 2025. The partnership with YouMeO plays exactly into this ambition, and it is another highly focused relationship that offers an excellent addition to our portfolio. We will focus on innovation with high impact for our clients.”
Axelle Paquer, Regional Leader France, Belgium, Luxembourg, and Africa at BearingPoint: “The integration of YouMeO, like the recent acquisition of French start-up Steerio, reflects our dynamic external growth strategy that is focused on the integration of structures with strong expertise. We are delighted with the creation of ‘YouMeO by BearingPoint,’ which has strong ambitions for the coming years.”
“Six years since our foundation, we wanted to have even more impact in our projects to support our customers’ strategy, innovation, and transformation, while continuing to rely on our two drivers: design and collective intelligence. So our merger with BearingPoint came about very naturally. Today, we are very pleased with the integration of the YouMeO team at BearingPoint, which will allow us to carry out even more ambitious and meaningful projects,” say Raphaël Beziz and Martin Mayer, co-founders of YouMeO.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business-critical services to its clients, supporting their business success. The third unit provides the software for successful digital transformation. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005729/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 10:22:00 CET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 22:42:00 CET | Press release
- Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) is the first systemic treatment for adult patients with advanced SCAC in Europe- The EC approval is based on results of the POD1UM-303 study which showed that adult patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment compared to chemotherapy alone.1 Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meur
Dfns Launches Payouts6.3.2026 21:27:00 CET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 20:23:00 CET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 18:30:00 CET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom